Skip to main content
Erschienen in: Supportive Care in Cancer 5/2017

09.01.2017 | Original Article

Prospective cohort study of cancer patients diagnosed with incidental venous thromboembolism on routine computed tomography scans

verfasst von: Carmen P. Escalante, Gregory W. Gladish, Wei Qiao, Ali Zalpour, Binara Assylbekova, Shuwei Gao, Kelechi A. Olejeme, Marsha N. Richardson, Maria E. Suarez-Almazor

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Venous thromboembolism (VTE) is a major complication of cancer with recent increasing reports of incidental VTE. The objectives are to estimate the prevalence of incidental VTE in cancer patients on staging CT scans, identify common symptoms, and determine VTE recurrence in a prospective study.

Patients and methods

One thousand ninety patients were studied. Adult cancer patients scheduled for outpatient staging CT scans were eligible. VTE cases were followed for 6 months. Fisher’s exact test for group comparisons of categorical variables and generalized linear modeling to estimate the prevalence of incidental VTE was used.

Results

The mean age was 58 years (range 18–87 years); 50% were male. The prevalence of incidental VTE was 1.8% (CI 1.15–2.87%). Significant symptoms in patients with VTE included fatigue (p = 0.004), stress (p = 0.0195), depression (p = 0.019), poorer quality of life (p = 0.0194), and poorer physical well-being (p = 0.0007). All the patients with VTE had at least one comorbidity (p = 0.03). No patient had recurrence within 6 months.

Conclusion

The prevalence of incidental VTE on staging CT scans is lower than previously reported. Symptoms were associated with VTE; however, further work is needed to understand whether these are clinically relevant. No VTE recurrences were noted following 6 months.
Literatur
1.
Zurück zum Zitat Khorana AA, Francis CW, Culakova E et al (2006) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24:494–490CrossRef Khorana AA, Francis CW, Culakova E et al (2006) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24:494–490CrossRef
2.
Zurück zum Zitat Sallah S, W.J., Nguyen NP, Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost, 2002. 87: p. 575–579. Sallah S, W.J., Nguyen NP, Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost, 2002. 87: p. 575–579.
3.
Zurück zum Zitat Stein PD, Beemath A, Meyers FA et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 4:60–68 Stein PD, Beemath A, Meyers FA et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 4:60–68
4.
Zurück zum Zitat Chew HK et al (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464CrossRefPubMed Chew HK et al (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464CrossRefPubMed
5.
Zurück zum Zitat Stein PD, Beemath A, Matta F et al (2007) Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED I. Am J Med 120(10):871–879CrossRefPubMedPubMedCentral Stein PD, Beemath A, Matta F et al (2007) Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED I. Am J Med 120(10):871–879CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Reidel M (2001) Acute pulmonary embolism 1: pathophysiology, clinical presentation and diagnosis. Heart 85:229–240CrossRef Reidel M (2001) Acute pulmonary embolism 1: pathophysiology, clinical presentation and diagnosis. Heart 85:229–240CrossRef
7.
Zurück zum Zitat Kucher N (2011) Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med 364:861–869CrossRefPubMed Kucher N (2011) Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med 364:861–869CrossRefPubMed
8.
Zurück zum Zitat O'Connell CL et al (2006) Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol 24(30):4928–4932CrossRefPubMed O'Connell CL et al (2006) Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol 24(30):4928–4932CrossRefPubMed
9.
Zurück zum Zitat Mendoza TR et al (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85(5):1186–1196CrossRefPubMed Mendoza TR et al (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85(5):1186–1196CrossRefPubMed
10.
Zurück zum Zitat Cleeland CS et al (2000) Assessing symptom distress in cancer patients: the M.D. Anderson symptom inventory. Cancer 89(7):1634–1646CrossRefPubMed Cleeland CS et al (2000) Assessing symptom distress in cancer patients: the M.D. Anderson symptom inventory. Cancer 89(7):1634–1646CrossRefPubMed
11.
Zurück zum Zitat Tanaka K et al (2002) Prevalence and screening of dyspnea interfering with daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manag 23(6):484–489CrossRef Tanaka K et al (2002) Prevalence and screening of dyspnea interfering with daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manag 23(6):484–489CrossRef
12.
Zurück zum Zitat Tanaka K et al (2000) Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale. Br J Cancer 82(4):800–805CrossRefPubMedPubMedCentral Tanaka K et al (2000) Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale. Br J Cancer 82(4):800–805CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Oken MM et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655CrossRefPubMed Oken MM et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655CrossRefPubMed
14.
Zurück zum Zitat Lovinbond SH, Lovibond PF (1995) Manual for depression, anxiety and stress scales, 2nd edn. Psyhology Foundation of Australia, Sydney Lovinbond SH, Lovibond PF (1995) Manual for depression, anxiety and stress scales, 2nd edn. Psyhology Foundation of Australia, Sydney
15.
Zurück zum Zitat Cella D, Hahn EA, Dineen K (2002) Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 11(3):207–221CrossRefPubMed Cella D, Hahn EA, Dineen K (2002) Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 11(3):207–221CrossRefPubMed
16.
Zurück zum Zitat Webster K, Cella D, Yost K (2003) The F unctional A ssessment of C hronic I llness T herapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 1:79CrossRefPubMedPubMedCentral Webster K, Cella D, Yost K (2003) The F unctional A ssessment of C hronic I llness T herapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 1:79CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Loud PA, Katz DS, Bruce DA et al (2001) Deep venous thrombosis with suspected pulmonary embolism: detection with combined CT venography and pulmonary angiography. Radiology 219:498–502CrossRefPubMed Loud PA, Katz DS, Bruce DA et al (2001) Deep venous thrombosis with suspected pulmonary embolism: detection with combined CT venography and pulmonary angiography. Radiology 219:498–502CrossRefPubMed
18.
Zurück zum Zitat Fujikawa A, Matsuoka S, Kuramochi K et al (2011) Vascular enhancement and image quality of CT venography: comparison of standard and low kilovoltage settings. AJR Am J Roentgenol 197:838–843CrossRefPubMed Fujikawa A, Matsuoka S, Kuramochi K et al (2011) Vascular enhancement and image quality of CT venography: comparison of standard and low kilovoltage settings. AJR Am J Roentgenol 197:838–843CrossRefPubMed
19.
Zurück zum Zitat Kaatz S et al (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119–2126CrossRefPubMed Kaatz S et al (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119–2126CrossRefPubMed
20.
Zurück zum Zitat Gladish GW et al (2006) Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history. Radiology 240(1):246–255CrossRefPubMed Gladish GW et al (2006) Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history. Radiology 240(1):246–255CrossRefPubMed
21.
Zurück zum Zitat Cronin CG et al (2007) Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol 189(1):162–170CrossRefPubMed Cronin CG et al (2007) Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol 189(1):162–170CrossRefPubMed
22.
Zurück zum Zitat Winston CB et al (1996) Incidental pulmonary emboli detected at helical CT: effect on patient care. Radiology 201(1):23–27CrossRefPubMed Winston CB et al (1996) Incidental pulmonary emboli detected at helical CT: effect on patient care. Radiology 201(1):23–27CrossRefPubMed
23.
Zurück zum Zitat Gosselin MV et al (1998) Unsuspected pulmonary embolism: prospective detection on routine helical CT scans. Radiology 208(1):209–215CrossRefPubMed Gosselin MV et al (1998) Unsuspected pulmonary embolism: prospective detection on routine helical CT scans. Radiology 208(1):209–215CrossRefPubMed
24.
Zurück zum Zitat Storto ML et al (2005) Incidental detection of pulmonary emboli on routine MDCT of the chest. AJR Am J Roentgenol 184(1):264–267CrossRefPubMed Storto ML et al (2005) Incidental detection of pulmonary emboli on routine MDCT of the chest. AJR Am J Roentgenol 184(1):264–267CrossRefPubMed
25.
Zurück zum Zitat Heit JA et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162(11):1245–1248CrossRefPubMed Heit JA et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162(11):1245–1248CrossRefPubMed
Metadaten
Titel
Prospective cohort study of cancer patients diagnosed with incidental venous thromboembolism on routine computed tomography scans
verfasst von
Carmen P. Escalante
Gregory W. Gladish
Wei Qiao
Ali Zalpour
Binara Assylbekova
Shuwei Gao
Kelechi A. Olejeme
Marsha N. Richardson
Maria E. Suarez-Almazor
Publikationsdatum
09.01.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3559-6

Weitere Artikel der Ausgabe 5/2017

Supportive Care in Cancer 5/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.